At a glance
ClinicalIndex Comparison RecordN/ACompleted· 724 enrolled
Drug / intervention
Trajenta duodrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Regulatory Requirement Non Interventional Study to Monitor the Safety and Effectiveness of Trajenta Duo® (Linagliptin/Metformin HCl, 2.5 mg/500 mg, 2.5 mg/850 mg and 2.5 mg/1000 mg, b.i.d) in Korean Patients With Type 2 Diabetes Mellitus
In Brief
An observational study evaluating Trajenta duo for Diabetes Mellitus, Type 2. Completed, enrolled 724 participants across 1 site.
Detailed Summary
The primary objective of this study is to monitor the safety profile of Trajenta Duo in Korean patients with type 2 diabetes mellitus (T2DM) in a routine clinical setting.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetes Mellitus, Type 2
CountriesSouth Korea
CollaboratorsEli Lilly and Company
Timeline
N/ACompletedFinished
2014201520162017201820192020202120222023202420252026
Enrollment StartJul 2013
First PostedJul 2013
Primary CompletionMay 2017
Study CompletionJun 2017
TodayJul 2026
First PostedJul 19, 2013
Enrollment StartJul 11, 2013
Primary CompletionMay 30, 2017
Study CompletionJun 10, 2017
TodayJul 2, 2026
Enrollment to primary: 3.9 yearsPosted 13.0 years ago
Interventions
Trajenta duodrug
Linagliptin and Metformin